This study is designed to investigate the effect of renal impairment on the safety and pharmacokinetics of SK3530 in subjects with renal impairment compared to healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
12
50mg Single Oral Dose of
Asan Medical Center
Seoul, South Korea
Pharmacokinetics (AUC and Cmax)
Time frame: 2days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.